REGENXBIO Inc. (RGNX)
NMS · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 29.7M | 30.3M | 6.4M | 108.0M |
| Gross Profit | 24.0M | 24.4M | (4.7M) | 107.0M |
| Operating Income | (52.4M) | (57.6M) | (83.4M) | 29.3M |
| Net Income | (61.9M) | (67.1M) | (90.1M) | 22.7M |
| Diluted EPS | $-1.20 | $-1.30 | $-1.72 | $0.43 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 112.7M | 90.2M | 83.3M | 170.4M |
| Gross Profit | 58.2M | 53.0M | 49.8M | 150.1M |
| Operating Income | (262.9M) | (268.1M) | (231.2M) | (161.2M) |
| Net Income | (280.3M) | (263.5M) | (227.1M) | (193.9M) |
| Diluted EPS | $-6.50 | $-6.02 | $-4.59 | N/A |